Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities
Cet article passe en revue les travaux récents sur l'utilité clinique de l'analyse de l'ADN libre circulant pour la prise en charge des patients atteints d'une tumeur solide
Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and metastatic cancers may allow the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression through ‘liquid biopsies’. The serial monitoring of tumor genotypes, which are instable and prone to changes under selection pressure, is becoming increasingly possible. The “liquid biopsy” provide novel biological insights into the process of metastasis and may elucidate signaling pathways involved in cell invasiveness and metastatic competence. This review will focus on the clinical utility of circulating cell free DNA in main solid tumors, including genetic and epigenetic alterations that can be detected.
Cancer treatment reviews , résumé, 2012